Lorazepam and New-Onset Dissociation: Taper the Cause or Taper It Carefully?
A truck driver's situational anxiety prescription has become a near-daily habit — and a new symptom, dissociation, that looks like it might be coming from the very drug meant to treat his anxiety. The disagreement is over how carefully, not whether, to take it away.
What frightens T.W. is not the accident. It is watching his own hands on the steering wheel as though they belong to somebody else, sounds arriving a beat delayed, the road going strange around him — and it happens most often a few hours after he takes his lorazepam. He is 52, has driven long-haul routes for twenty-six years, and has started skipping his afternoon dose on days he is dispatched, specifically because of this. Skipping it has made his daytime anxiety worse. The lorazepam dates to a winter storm two years ago, when he jackknifed his trailer on an icy overpass — no injuries, no other vehicles, but a fright that stayed with him in a way nothing else on the road ever had. His primary care physician started it as needed, for situational anxiety and for sleep before overnight runs. Over the months that followed the as-needed use quietly became near-daily: 1mg most mornings, sometimes a second dose before a long night route, and on nights when sleep would not come at all, sometimes a third. He has told neither his employer nor his safety supervisor, because a commercial driver's license carries direct and concrete stakes tied to what gets disclosed about medication use, and he has so far kept driving without incident.
Two mechanisms could produce what he is describing, and the case turns on which is doing more of the work. Benzodiazepines potentiate GABA-A signaling, and paradoxical reactions to this class are documented — Mancuso and colleagues' 2004 review catalogued them across the case literature — though that review is careful that such reactions occur in under 1% of patients, that their mechanism remains unclear, and that most appear idiosyncratic rather than predictable from dose or duration. Set against that is the timing he reports. Lorazepam is short-acting, he has taken it near-daily for roughly eighteen months, and symptoms arriving several hours after a dose are the signature of falling drug levels rather than peak effect — which would make this interdose withdrawal, not a direct drug effect. The distinction is not academic: one of those mechanisms gets better the moment the drug is reduced, and the other gets temporarily worse.
Whose symptom is this
Whichever mechanism is dominant, the drug is the common term in both. Mancuso and colleagues' 2004 review is the standard catalogue of paradoxical benzodiazepine reactions, and I'll be honest about its limits — under 1% incidence, mechanism unclear, most cases idiosyncratic rather than dose-predictable. What I'm relying on more is the timing: symptoms several hours after a short-acting agent taken near-daily for eighteen months look like falling levels, not peak effect. I'd taper him off lorazepam as the primary intervention. Continuing or increasing the drug he's currently avoiding out of fear would predictably worsen the exact symptom bringing him in.
You're right that the pharmacologic mechanism is real and worth acting on — I'm not disputing that. But I want two things held alongside it. First, the accident itself is a genuine trauma-adjacent event that hasn't been formally evaluated; if there's an underlying anxiety or stress-response process the lorazepam was only ever masking, a taper alone won't resolve that. Second — and this follows directly from your own interdose-withdrawal reading, which I think is right — if what he is experiencing already is withdrawal between doses, then a fast taper is simply a larger version of the thing making him ill. It would produce more of the exact symptom he came in frightened by, and we would have no clean way to tell it apart from his presenting complaint.
I don't think "how fast we taper" is actually a reason to delay tapering — it's the answer to exactly the concern just raised. A measured, properly paced reduction, spacing dose decreases appropriately rather than cutting the dose sharply, is specifically designed to minimize withdrawal-related perceptual symptoms; that's not a competing plan to tapering, it's what responsible tapering already means.
Given his occupation, pacing matters for a second, practical reason too — he can't be meaningfully impaired mid-route. I'd start a gradual, scheduled dose reduction now, coordinate the schedule around his driving calendar rather than a fixed calendar, and refer him for the trauma evaluation in parallel rather than as a precondition for starting.
Agreed: begin a gradual, scheduled lorazepam taper, with the reduction pace coordinated around his driving calendar rather than a fixed calendar, alongside a parallel referral for evaluation of the underlying trauma-adjacent anxiety from his accident.
Not fully agreed:
Favor a somewhat faster reduction schedule, given how distressing the current dissociative episodes already are for him.
Favors a more conservative pace specifically because of the occupational stakes — even a low probability of a withdrawal-related episode mid-route is a risk worth weighting heavily.
The team split the difference for the first two dose reductions and agreed to revisit the pace explicitly at his next visit based on how he tolerates them, rather than commit to a full schedule neither position was fully comfortable with today.